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Abstract
Background: Secondary preventive drug therapy following acute myocardial infarction (AMI) is recommended to
reduce the risk of new cardiovascular events. The aim of this nationwide cohort study was to examine the initiation
and long-term use of secondary preventive drugs after AMI.
Methods: The prescription of drugs in 42,707 patients < 85 years discharged alive from hospital after AMI in
2009–2013 was retrieved by linkage of the Norwegian Patient Register, the Norwegian Prescription Database,
and the Norwegian Cause of Death Registry. Patients were followed for up to 24 months.
Results: The majority of patients were discharged on single or dual antiplatelet therapy (91 %), statins (90 %),
beta-blockers (82 %), and angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor II blockers
(ARB) (60 %). Patients not undergoing percutaneous coronary intervention (PCI) (42 %) were less likely to be
prescribed secondary preventive drugs compared with patients undergoing PCI. This was particular the case for
dual antiplatelet therapy (43 % vs. 87 %). The adherence to prescribed drugs was high: 12 months after index
AMI, 84 % of patients were still on aspirin, 84 % on statins, 77 % on beta-blockers and 57 % on ACEI/ARB. Few
drug and dose adjustments were made during follow-up.
Conclusion: Guideline-recommended secondary preventive drugs were prescribed to most patients discharged from
hospital after AMI, but the percentage receiving such therapy was significantly lower in non-PCI patients. The long-time
adherence was high, but few drug adjustments were performed during follow-up. More attention is needed to secondary
preventive drug therapy in AMI patients not undergoing PCI.
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Background
Ischemic heart disease is a common cause of death in in-
dustrialized countries and accounts for a large proportion
of hospital admissions in Norway [1]. Approximately
13,000 men and women are diagnosed annually with acute
myocardial infarction (AMI) [2]. Secondary preventive
drug therapy, e.g. platelet inhibitors, statins, beta-blockers
and angiotensin-converting enzyme inhibitors (ACEI)/
angiotensin receptor II blockers (ARB), is recommended
following AMI to reduce the risk of new cardiovascular
events and death [3–7]. However, an underuse of
secondary preventive drugs has previously been observed
following AMI, especially in patients not undergoing per-
cutaneous coronary intervention (PCI) [8]. Despite their
elevated cardiovascular risk [9], still many AMI patients
are not treated according to guidelines [10]. This may be
related to under-prescription, reduced adherence, and/or
under-dosing of secondary preventive drug therapy
[11, 12]. A potential source for the underuse of recom-
mended secondary preventive drugs could be the shift
of treatment responsibility from the hospitals to the
general practitioners in the primary care setting. The
extent to which the hospital-initiated treatment is
continued as initially prescribed, the doses adjusted or
drugs switched to another type of drug within the
same drug class, is not known. Comprehensive analyses of
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initiation and adherence in different patient populations
are essential to improve long-term use of secondary pre-
ventive drugs and cardiovascular outcomes [13].
The aim of this nationwide cohort study was to examine
the initiation and long-term use of secondary preventive
drug in patients hospitalized with AMI in Norway during
the years 2009 to 2013.
Methods
Data sources
This observational, historical cohort study was based
on data from three Norwegian national registries: 1)
The Norwegian Patient Register covering all hospital
admissions and including diagnoses according to the
International Classification of Diseases, 10th revision,
Clinical Modification (ICD-10-CM) [14]; 2) the Nor-
wegian Prescription Database registering all pharmacy
dispenses [15]; and 3) the Norwegian Cause of Death
Registry registering all deaths [16]. The prescription of
drugs in patients discharged alive from hospital after
AMI in 2009–2013 was retrieved by linkage of the
Norwegian Patient Register, the Norwegian Prescrip-
tion Database, and the Norwegian Cause of Death
Registry. Patients were followed for up to 24 months.
The Norwegian Institute of Public Health performed
the data linkage. Data were anonymised before further
analysis. The linked database was managed by The
Norwegian University of Science and Technology,
Trondheim, Norway.
Study population
All patients below 85 years of age who were admitted to
hospital with a primary diagnosis of AMI (index AMI)
(ICD-10: I21) between 1 January 2009 and 30 November
2013 and alive 30 days after discharge were included in
this study. Patients 85 years or older were excluded for
two reasons: 1) their likelihood of long-term use of
secondary preventive drugs might be extensively con-
founded by fragility; 2) older patients have an in-
creased risk of long-term institutional stays where the
drug use cannot be captured by the available registries.
Patients were classified as PCI and non-PCI patients
depending on whether PCI was performed or not up to 30
days after index-AMI. The study population was further
stratified into two groups; ≤75 years and 76–84 years.
Index AMI was defined as the first recorded primary
diagnosis of AMI for a patient during the specified
time-period (not necessarily the patient’s first AMI).
All residents in Norway are covered by a national
health security system with a universal tax-funded ac-
cess to primary and secondary health care, including
secondary preventive drugs recommended after AMI.
Follow-up
Observational data on drug prescriptions were collected
up to 24 months following AMI, or until 31 December
2014 or death (whichever occurred first).
Drug treatment and adherence
Drug treatment at discharge for index AMI were calcu-
lated from dispensed drugs from pharmacies one year
within and until 30 days after the index AMI; either a
prior dispensing covering day 0 to day 30 or a new dis-
pensing within day 0 to day 30. Drug adherence was de-
fined as the proportion of patients on the treatment of
interest at each day from 12 months prior to the date of
hospitalization for AMI until a maximum of 24 months
after. The calculation of drug use (days on treatment)
was based on the prescribed dose and on the number of
pills collected or delivered from the pharmacies. Whether
or not the pills were taken by the patients, were not
assessed. If a patient had a gap in collection of drugs, the
patient was defined as a non-user from last calculated day
with available drug. Furthermore, if a patient after a gap,
again collected the same drug from the pharmacy, the
patient was defined as a user from that actual date, and if
a patient was switched to another type of drug within the
same drug class after the index AMI episode, the patient
was defined as a user.
In the separate analysis of the adherence to the P2Y12-
antagonists clopidogrel, prasugrel or ticagrelor during
the first 18 months after AMI, the proportion of all pa-
tients still alive continuing on the same P2Y12 antagonist
as at discharge was estimated.
In order to describe changes in drug treatment over
time, treatment at discharge for index AMI was com-
pared to treatment in the post AMI period (dispensed
during 12 18 months after the AMI).
Statistical analyses
Data are presented as mean with standard deviation for
continuous variables and absolute and relative frequencies
for categorical variables. Patients were stratified by age
(≤75 years or 75–84 years) and by PCI status (PCI or no
PCI). Statistical analyses were performed using SAS ver-
sion 9.3 (SAS Institute Inc, Cary, NC, USA) and R version
3.2.2 [17].
Results
A total of 57,106 individuals were admitted to Norwegian
hospitals for AMI during the study period, of whom
45,838 (80.3 %) were younger than 85 years. Of these,
42,707 (93.2 %) were alive 30 days after hospital discharge
and could be included in the study (Fig. 1). Overall, 70 %
of the patients were men and mean age was 65.8 years
(standard deviation 11.8) (Table 1). A total of 58 % of the
patients underwent PCI, with an increasing proportion
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during the study period (from 53 % to 63 %) (Additional
file 1, Table 1). Patients undergoing PCI were younger and
more often male compared with the medically treated
patients (Table 1).
Initiation of secondary preventive drugs
The prescription of secondary preventive drugs at discharge
is shown in Tables 1 and 2. The majority of patients were
discharged on single or dual antiplatelet therapy (DAPT)
(19 % and 72 %, respectively), statins (90 %), beta-blockers
(82 %), and ACEI/ARB (60 %). The percentage receiving
these drugs were slightly lower in patients 75–84 years
compared to patients ≤75 years, except for ACEI/ARB
which was prescribed slightly more often in the elderly
(Table 1).
Patients undergoing PCI were prescribed secondary
preventive drug therapy more often than patients not
undergoing PCI (Table 1). This was the case both for pa-
tients <75 years and patients 75–84 years. The difference
in prescriptions was largest with respect to DAPT, which
was prescribed in 92 % of the PCI patients vs. 45 % of
patients not undergoing PCI (Table 1, Figs. 2 and 3). In
contrast, non-PCI patients were prescribed other kinds
of antithrombotic therapy more often than PCI patients:
Aspirin monotherapy in 28 % vs. 2 %, oral anticoagulant
(OAC) monotherapy in 4 % vs. 0 %, or OAC in combin-
ation with single antiplatelet therapy in 6 % vs. 1 %, re-
spectively. However, 14 % of the non-PCI patients were
discharged with neither antiplatelet drugs nor OAC,
compared to 2 % of the PCI patients. Surprisingly, the
differences in prescription pattern between PCI and
non-PCI patients were found also with respect to other
types of secondary preventive drugs (Table 1).
The mean dose of statins at discharge was 37 mg for
simvastatin (55 % of patients) and 57 mg for atorvastatin
(40 % of patients). The mean doses of ACEI/ARB and
beta-blocker at discharge were 35-60 % and 30-50 % of
maximal recommended doses, respectively (Table 2).
Adherence to secondary preventive drugs
The overall long-time adherence was high among all pa-
tients initiated on treatment with statins, beta-blockers
and ACEI/ARB (Figs. 2 and 3, Table 2). The proportions
of patients using statins, ACEI/ARB and beta-blockers
Fig. 1 Flow chart of the study population
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were reduced by 6 %, 3 % and 4 %, respectively, after
one year. No major differences in drug adherence was
observed between PCI and non-PCI patients, or between
patients ≤75 and 76–84 years. When primary health care
physicians took over the prescription responsibility for
these patients (approximately 3 months after the AMI),
no overall change in adherence was found. Approxi-
mately 20 % of patients changed to another drug within
the same drug class, or changed the dose of statin, beta-
blocker and ACEI/ARB within 12–18 months after the
AMI (Table 2).
The adherence to antiplatelet drugs was also high (Figs. 2
and 3). After 12 months, 84 % of patients were still on as-
pirin; 83 % after 18 months. The adherence to P2Y12 in-
hibitors are shown in more detail in Fig. 4 and Additional
file 1: Table S2. Patients not undergoing PCI had a shorter
length of time on treatment with a P2Y12 inhibitor com-
pared with PCI patients, with a substantial proportion of
these patients discontinuing treatment already after three
months. The majority of the PCI patients treated with
ticagrelor and prasugrel maintained the treatment through
12 months. Many PCI patients on clopidogrel discontin-
ued P2Y12 inhibitor after nine months.
Discussion
This nationwide observational cohort study, including
all patients younger than 85 years surviving an AMI in
Norway during the years 2009 to 2013, showed a generally
high long-term adherence to the prescribed treatment
with antiplatelet drugs, statins, beta-blockers and ACEI/
ARB. The shift of responsibility for prescribing secondary
preventive drugs from hospital to primary health care
showed a sustained high use of the originally prescribed
drugs. Only few patients switched to another type of statin
or changed the dose of statin, beta-blocker and ACEI/
ARB during the first two years after the AMI. For patients
not undergoing PCI, a smaller proportion was discharged
with secondary preventive drugs following their AMI
compared with patients undergoing PCI, and less than
half were prescribed DAPT at discharge.
Contemporary national level data describing long-
term adherence to secondary preventive medications,
i.e. antiplatelet drugs, statins, beta-blockers, and ACEI/
ARB in AMI populations comparing younger vs. older
and PCI vs. non-PCI patients are scarce. Furthermore,
little is known on the impact of change in drug treat-
ment responsibilities as AMI patients are transferred
from hospital care to primary health care.
The initiation of secondary preventive drugs in our
study was considerably higher than was found in a
previous Danish nationwide study [12]. In patients ad-
mitted with a first AMI between 1995 and 2002 in
Denmark, only 58 % received beta-blockers, 29 %
ACE-inhibitors, and 34 % statins at discharge [12].
Table 1 Drug treatment at discharge after index AMI. Patients stratified by age (≤75 years or 75–84 years) and by PCI status (PCI or
no PCI)
Age ≤75 years Age 75–84 years Total
n = 30 843 n = 11 864 n = 42 707
PCI No PCI PCI No PCI
n = 19 835 n = 11 008 n = 4918 n = 6946
(64.3) (35.7) (29.3) (70.7)
Women 4065 (20.5) 3478 (31.6) 1819 (37.0) 3357 (48.3) 12 719 (29.8)
Age, mean (SD) 59.8 (9.1) 61.6 (9.6) 79.0 (2.8) 80.0 (2.8) 65.8 (11.8)
DAPT 17 505 (88.3) 5107 (46.4) 3877 (78.8) 2597 (37.4) 29 086 (68.1)
Only P2Y12 inhibitor 668 (3.4) 354 (3.2) 202 (4.1) 295 (4.3) 1519 (3.6)
Only ASA 288 (1.5) 3105 (28.2) 151 (3.1) 1860 (26.7) 5404 (12.3)
Only OAC 21 (0.1) 312 (2.8) 15 (0.3) 339 (4.9) 687 (1.6)
OAC + DAPT 925 (4.7) 241 (2.2) 473 (9.6) 165 (2.4) 1804 (4.2)
OAC + P2Y12 inhibitor 58 (0.3) 40 (0.4) 28 (0.6) 58 (0.8) 184 (0.4)
OAC + ASA 43 (0.2) 520 (4.7)) 32 (0.7) 529 (7.6) 1124 (2.6)
No antiplatelet or OAC 327 (1.7) 1329 (12.1) 140 (2.9) 1103 (15.9) 2899 (6.8)
Statins 19 168 (96.6) 9224 (83.8) 4574 (93.0) 5262 (75.7) 38 228 (89.5)
Beta-blockers 16 763 (84.5) 8529 (77.5) 4238 (86.2) 5456 (78.6) 34 986 (81.9)
ACE inhibitors 7977 (40.3) 3478 (31.7) 2027 (41.2) 2497 (36.0) 15 988 (37.4)
ARB 4822 (24.3) 2945 (26.8) 1597 (32.5) 2072 (29.8) 11 346 (26.8)
Numbers in parentheses are percentages of total number of patients in the group. SD denotes standard derivation, DAPT dual antiplatelet therapy, AMI Acute
myocardial infaction, ASA Acetylsalicylic acid, OAC Oral anticoagulants, ACE Angiotensin-converting enzyme, ARB Angiotensin II receptor blocker
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Table 2 Secondary preventive drugs at discharge from hospital for index AMI and 12˗18 months later; patients <85 years
Secondary preventive drugs
at discharge for index AMI
Secondary preventive drugs
12–18 months after index AMI
(n = 42 707) (n = 28 767)
n (%) Mean dose (mg) n (%) Mean dose (mg) n (%) switched to another drug
within same drug class in
post-AMI period
n (%) changed dose of actual
drug in post-AMI period
Statins 38 228 (89.5) 24 062 (83.6)
Simvastatin 23 528 (55.1) 37.2 12 478 (43.4) 38.4 2571 (15.7) 1415 (8.7)
Atorvastatin 17 084 (40.0) 56.9 10 913 (37.9) 52.1 592 (6) 1755 (17.8)
Rosuvastatin 225 (0.5) 17.7 367 (1.3) 19.6 10 (9.6) 13 (12.5)
Pravastatin 1158 (2.7) 33.5 651 (2.3) 33.5 120 (20.9) 39 (6.8)
ACEI/ARBa 25 445 (59.6) 16 274 (56.6)
Losartan 3658 (8.6) 66.6 2049 (7.1) 66.5 153 (6.9) 238 (10.8)
Candersartan 4157 (9.7) 13.1 2778 (9.7) 13.5 145 (5.4) 467 (17.4)
Valsartan 1503 (3.5) 124.9 865 (3.0) 125.2 68 (7.2) 127 (13.4)
Irbesartan 1530 (3.6) 235.6 770 (2.7) 237.3 72 (7.8) 61 (6.6)
Enalapril 2951 (6.9) 11.8 1657 (5.8) 11.9 170 (8.9) 324 (16.9)
Ramipril 11 492 (26.9) 3.5 6999 (24.3) 4.5 733 (8.8) 2156 (25.8)
Lisinopril 1753 (4.1) 11.3 949 (3.3) 11.3 121 (10.3) 207 (17.5)
Beta-blockers 34 986 (81.9) 22 061 (76.7)
Metoprolol 30 874 (72.3) 60.6 18 920 (65.8) 62.3 702 (3.2) 4452 (20.3)
Atenolol 1381 (3.2) 52.4 457 (1.6) 51.0 117 (21.6) 54 (10)
Propranolol 305 (0.7) 66.2 82 (0.3) 80.4 26 (26.3) 6 (6.1)
Sotalol 358 (0.8) 80.3 138 (0.5) 75.9 49 (33.3) 14 (9.5)
Bisoprolol 2477 (5.8) 4.1 1856 (6.5) 4.4 64 (4) 310 (19.3)
Carvedilol 1298 (3.0) 15.8 813 (2.8) 15.6 73 (9.1) 123 (15.3)
Numbers in parentheses are percentages of total number of patients in the group
ACEI Angiotensin-converting enzyme inhibitor, AMI Aciute myocardial infraction, ARB Angiotensin II receptor blocker














Although long-term compliance was reasonably good,
patients who did not start treatment shortly after dis-
charge had a low probability of starting treatment later
[12]. In a more recent Swedish study, both initiation
and long-term adherence to secondary preventive drug
therapy was higher and similar to our findings: 82 %
of AMI patients were still on aspirin 12 months post
AMI, 73 % on statins and 80 % on beta-blockers [18].
A high degree of initiation of secondary preventive
drug therapy was also observed in a recent study from
the United States [13]. However, when patients were
divided into risk groups based on the Global Registry
of Acute Coronary Event (GRACE) risk score at hospital
discharge, high-risk patients had a lower likelihood of re-
ceiving all appropriate therapies at discharge compared
with low-risk patients.
Fig. 2 Adherence to secondary preventive drugs over time in AMI patients ≤75 years with or without PCI. Norway 2009–2013. Abbreviations: ASA,
acetylsalicylic acid; ACEI, angiotensin-converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin II receptor blocker; PCI,
percutaneous coronary intervention
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Our data may indicate that if secondary preventive
drug therapy after AMI is not prescribed at hospital
discharge, the likelihood of receiving such treatment is
limited. Thus, initiation of guideline-recommended second-
ary preventive drug therapy after AMI seems to depend on
the hospital physicians, in accordance with the previous ob-
servations from Denmark [12]. The present study further
demonstrates that only minor dose adjustments for drugs
prescribed at discharge were performed by the primary care
physicians during follow-up. Thus, Norwegian primary care
physicians seemed reluctant to changing already prescribed
secondary preventive drug therapies after AMI.
This finding further underscores the importance of drug
prescription prior to discharge of AMI patients from hospi-
tals. Not only should AMI patients be prescribed guideline-
recommended secondary preventive drugs, but the hospital
Fig. 3 Adherence to secondary preventive drugs over time in AMI patients 76–84 years with and without PCI. Norway 2009–2013. Abbreviations:
ASA, acetylsalicylic acid; ACEI, angiotensin-converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin II receptor blocker; PCI,
percutaneous coronary intervention
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physicians could also advice on further up-titration and the
target doses of the prescribed drugs in the discharge sum-
mary sent to the patient’s general practitioner. It is also
important that the general practitioners are updated
on current guidelines and take the responsibility for
optimizing secondary preventive treatment after AMI.
Interestingly, patients not undergoing PCI were less
likely to receive guideline-recommended secondary
preventive drugs compared with patients undergoing
PCI. For example, a 10–20 % higher use of statins and
beta-blockers was seen in PCI patients vs. patients not
undergoing PCI. Furthermore, a larger portion of pa-
tients not undergoing PCI was discharged without a
P2Y12 inhibitor (48 % and 55 %, respectively, in pa-
tients ≤75 or 76–84 years) compared with PCI patients
(4 % and 7 %). The reasons for this undertreatment of
non-PCI patients are not known. We might speculate
that a higher degree of comorbidities might be present
in these patients, making the physicians more selective
in their prescription of secondary preventive drugs.
Fig. 4 Adherence to treatment with different P2Y12 inhibitors in AMI patients <85 years with and without PCI. Norway 2009–2013. Abbreviations:
AMI, acute myocardial infarction; PCI, percutaneous coronary intervention
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The mean doses of both ACEI, ARB and beta-blockers
in our study were lower than the target doses in ran-
domized trials studying the efficacy and safety of these
drugs. The reasons for the choice of these lower doses,
or the lack of up-titration of doses after hospital dis-
charge, are unknown. These drugs are used for a variety
of indications, and since we have limited data on weight,
blood pressure, heart rate, ejection fraction, comorbidi-
ties and on the specific indications for the various drugs
(e.g. for ACEI/ARB), we find it difficult to draw any firm
conclusions regarding target doses and whether the
doses used in our study were too low or not. With re-
spect to statin treatment, it should be noted that during
most of our study period, no specific statin dose was
recommended and statins were prescribed mainly ac-
cording to LDL-cholesterol levels.
We observed a generally short duration of P2Y12 in-
hibitor treatment for patients not undergoing PCI
(Fig. 4), with a significant proportion of patients treated
for only three months as also observed in a recent study
from Sweden [19]. One possible reason for the longer
treatment duration after PCI may be that P2Y12 inhib-
ition is regarded particularly important after stent im-
plantation to avoid stent thrombosis. However, ESC
guidelines recommend P2Y12 inhibition for 12 months in
all ACS patients [3–6].
A large proportion of patients discontinued P2Y12 in-
hibitor after nine months; mainly patients on clopido-
grel treatment. One likely explanation to this finding
was the nine months’ limited reimbursement of clopi-
dogrel in Norway until September 2011 [20]. Prasugrel
and ticagrelor have not had such reimbursement limita-
tions. This finding demonstrates the influence the
health authorities have on medical treatment by deter-
mining the prescription rules for reimbursements of
various drugs.
Limitations
Our data set provides a unique possibility to examine
adherence to antiplatelet therapy, statins, beta-blockers
and ACEI/ARB. It includes nationwide data from all pa-
tients hospitalized in Norway for AMI in 2009–2013,
allowing analyses of a complete and unselected cohort of
patients, and also allowing differentiation between younger
and older patients and between patients undergoing PCI or
not. This reduces potential problems arising from selection
bias due to inclusion of selected hospitals, regions, or health
care insurance systems. Furthermore, by restricting the
inclusion to patients below 85 years of age, this study
focuses on patients who normally would be considered to
be treated according to guidelines. However, this register-
based analysis also has certain limitations. As our analysis
relied on ICD-10 codes, the possibility of coding errors can-
not be ruled out, although the primary diagnoses of AMI
previously have been shown to have high sensitivity and
specificity [21]. A further subclassification of patients into
those presenting with and without persistent ST-segment
elevation on the electrocardiogram could not be per-
formed due to non-validated ICD-10 coding specifica-
tion at this level.
Further, due the study aim describing secondary
drug adherence in a nationwide patient population,
patients were included based on their first AMI during
the observational period, i.e. not necessarily their first
time AMI. Thus, the patient population changed dur-
ing the inclusion period. While patients included early
in the inclusion period may have had a recent history
of AMI, patients included towards the end of the
study period had to be event-free for a longer time.
Following from this study design, the yearly numbers
of included AMIs in our study decreased during the
observational period (Additional file 1, Table 1). Fur-
thermore, how a recent prior AMI episode would
affect selection for invasive treatment and secondary
prevention drugs is difficult to predict, but it cannot
be excluded that these patients would receive a higher
attention, and thus a higher likelihood of receiving
guideline-recommended treatment.
The registry data were collected for administrative pur-
poses and we did not have any information on smoking
patterns, weight, blood pressure, laboratory data or socio-
economic status. Furthermore, the Norwegian Patient
Register has only had nationwide coverage since 2009 and
medical history from previous hospitalizations was not
available.
Conclusions
This nationwide observational study, including all pa-
tients in Norway below 85 years of age being alive 30
days after AMI during the years 2009 to 2013, showed a
generally high long-term adherence to antiplatelet ther-
apy, as well as treatment with statins, beta-blockers and
ACEI/ARB. To a large extent, PCI patients received
guideline-recommended treatment with secondary pre-
ventive drugs. Patients not undergoing PCI were less
likely to be discharged with the recommended drugs.
The shift of responsibility for prescribing drug treat-
ment from hospital to primary health care did not to
any major extent alter the already prescribed treat-
ments. Thus, the majority of AMI patients remained on
the secondary preventive treatment originally pre-
scribed, further underlining the importance of prescrib-
ing guideline-recommended drug treatment at hospital
discharge, and preferably including specialist guidance
on future target doses in the discharge summary. The
present study also indicates a need for more careful at-
tention to secondary preventive drug therapy in AMI
patients not undergoing PCI.
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